Latest Biotechnology, Pharmaceutical and Healthcare News from Cancer Networks

19:53 EDT 22nd October 2018 | BioPortfolio

Here are the most relevant search results for "Cancer Networks" found in our extensive news archives from over 250 global news sources.

More Information about Cancer Networks on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cancer Networks for you to read. Along with our medical data and news we also list Cancer Networks Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cancer Networks Companies for you to search.

Showing News Articles 1–25 of 516 from Cancer Networks

Monday 22nd October 2018

Link Found Between mTORC1, G2/M DNA Damage Checkpoint

Guang Peng, MD, PhD spoke to Cancer Network about the recent discovery that mTORC1 can help determine cell fate after DNA damage.

While Pregnancy May Be Possible After Chemo, How Many Patients’ Plans Change?

While becoming pregnant is generally possible for younger breast cancer patients, researchers believe many women change their minds after treatment.

Maintenance Olaparib Yields Impressive Results in Advanced Ovarian Cancer

Researchers tested whether 2 years of maintenance therapy with olaparib would improve outcomes in advanced ovarian cancer patients.

Can Patients With HIV and a Cancer Diagnosis Safely Receive Immunotherapy?

Researchers tested whether immunotherapy could be safely used in HIV-positive patients with cancer.

Friday 19th October 2018

What Caused Neck Pain in This 73-Year-Old Man?

A 73-year-old man presents with neck pain and a mass of possible thyroid origin. What is your diagnosis?

Can Low-Dose Aspirin Lower Ovarian Cancer Risk?

Regular users of low-dose aspirin appear to have a reduced risk of developing ovarian cancer, according to a new study.

Using Exosomes to Help Cancer Diagnosis

Dr. Raghu Kalluri speaks with Cancer Network about the role of exosomes in cancer progression ahead of his presentation at ESMO 2018.

Recognizing Nonadherence to Tamoxifen in Early Breast Cancer Patients

In premenopausal patients with early breast cancer, approximately one-sixth are not adequately adherent to adjuvant endocrine therapy.

Thursday 18th October 2018

What Caused the Intranasal Mass in This Woman's Nose?

A 52-year-old woman presents with nasal congestion and an intranasal mass. What is your diagnosis?

Monitoring Residual Disease in Colon Cancer

Dr. Luis Diaz spoke with Cancer Network about monitoring for residual disease in colon cancer ahead of his presentation at ESMO 2018.

Recognizing the Side Effects of Newly Approved CLL Therapies

Dr. Ian Flinn spoke with Cancer Network about incorporating the newest approved therapies for the management of CLL.

Do Some Prostate Cancer Therapies Raise Patients’ Risks for Bladder Cancer?

Treatment for prostate cancer with external beam radiotherapy was found to be associated with an increased risk for development of bladder cancer when compared with radical prostatectomy.

The Black Box in Cancer: Dealing With the Unthinkable

In his latest blog, Craig Hildreth explores the terror of the black box warning and how the fear of toxicities affects his patients—and his staff.

Wednesday 17th October 2018

Herb-Drug Interactions in Cancer Care

In this article, we describe the mechanisms via which interactions between herbs and prescription drugs may occur, and highlight four popular herbs and a medicinal mushroom commonly used by cancer patients, along with reports of their interactions with standard drugs.

Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer

An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her?

Gene Expression Assays in Early-Stage Breast Cancer

Dr. Sparano discusses the implications of TAILORx, the first trial to use Oncotype DX in clinical decision making.

When to Order an MRI in the Initial Evaluation and Management of Prostate Cancer

This article summarizes the current role of multiparametric MRI in the diagnosis, risk assessment, and treatment of prostate cancer.

A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue

Due to the high rate of EGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.

Integrating Immunotherapy Into Colorectal Cancer Care

Until recent studies were reported, immunotherapy was thought to be ineffective for colorectal cancer; this article provides guidance on how to incorporate immunotherapy into this setting.

Managing Psychosocial Distress: Lessons Learned in Optimizing Screening Program Implementation

This article discusses “lessons learned” on managing psychosocial distress and the optimal strategies to promote institutions’ adoption of distress screening.

Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going

This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer.

What Role Will Avelumab Play in Lung Cancer?

The anti–PD-L1 agent avelumab did not improve overall survival compared with docetaxel in patients with PD-L1–positive non–small-cell lung cancer.

Study: Best Treatments for Basal Cell Carcinoma

When treating low-risk primary basal cell carcinoma (BCC), surgery and external beam radiation yield a better chance of a cure and a lower recurrence rate compared with other treatment modalities. This is the finding of a recent meta-analysis published in the Annals of Internal Medicine.

Tuesday 16th October 2018

Does Frailty Predict for Complications After Bladder Cancer Surgery?

Measures of frailty and comorbidity failed to offer predictive information regarding complications in patients with bladder cancer undergoing radical cystectomy.

Significance of MHC-II in Immunotherapy

While previous research has proven the role MHC-I molecules play, a new study in Cell suggests that MHC-II may also play a role in immunotherapy.

Quick Search


News Quicklinks